Unmet needs and new models for future trials in autoimmune hepatitis

David Jones, Michael P. Manns, Luigi Terracciano, Michael Torbenson, John M. Vierling

Research output: Contribution to journalComment/debate

1 Citation (Scopus)

Abstract

Despite advances in understanding and treatment of autoimmune hepatitis, important unmet clinical needs remain in both adult and paediatric patient populations. The evolving research landscape and assembly of large patient cohorts are creating unique opportunities to translate science into new therapies and care pathways, with the potential to substantially improve the lives of patients with autoimmune hepatitis. However, these areas of unmet need represent real challenges that need to be addressed if this vision is to be realised. In this Viewpoint, we outline the challenges in adult autoimmune hepatitis, particularly in relation to disease-modifying therapy, and trial design and delivery. Paediatric autoimmune hepatitis presents its own set of challenging problems.

Original languageEnglish (US)
Pages (from-to)363-370
Number of pages8
JournalThe Lancet Gastroenterology and Hepatology
Volume3
Issue number5
DOIs
StatePublished - May 1 2018

Fingerprint

Autoimmune Hepatitis
Pediatrics
Therapeutics
Research
Population

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Unmet needs and new models for future trials in autoimmune hepatitis. / Jones, David; Manns, Michael P.; Terracciano, Luigi; Torbenson, Michael; Vierling, John M.

In: The Lancet Gastroenterology and Hepatology, Vol. 3, No. 5, 01.05.2018, p. 363-370.

Research output: Contribution to journalComment/debate

Jones, David ; Manns, Michael P. ; Terracciano, Luigi ; Torbenson, Michael ; Vierling, John M. / Unmet needs and new models for future trials in autoimmune hepatitis. In: The Lancet Gastroenterology and Hepatology. 2018 ; Vol. 3, No. 5. pp. 363-370.
@article{1b89ed6689c846cf97123a7d591ac7f5,
title = "Unmet needs and new models for future trials in autoimmune hepatitis",
abstract = "Despite advances in understanding and treatment of autoimmune hepatitis, important unmet clinical needs remain in both adult and paediatric patient populations. The evolving research landscape and assembly of large patient cohorts are creating unique opportunities to translate science into new therapies and care pathways, with the potential to substantially improve the lives of patients with autoimmune hepatitis. However, these areas of unmet need represent real challenges that need to be addressed if this vision is to be realised. In this Viewpoint, we outline the challenges in adult autoimmune hepatitis, particularly in relation to disease-modifying therapy, and trial design and delivery. Paediatric autoimmune hepatitis presents its own set of challenging problems.",
author = "David Jones and Manns, {Michael P.} and Luigi Terracciano and Michael Torbenson and Vierling, {John M.}",
year = "2018",
month = "5",
day = "1",
doi = "10.1016/S2468-1253(18)30043-8",
language = "English (US)",
volume = "3",
pages = "363--370",
journal = "The Lancet Gastroenterology and Hepatology",
issn = "2468-1253",
publisher = "Elsevier Limited",
number = "5",

}

TY - JOUR

T1 - Unmet needs and new models for future trials in autoimmune hepatitis

AU - Jones, David

AU - Manns, Michael P.

AU - Terracciano, Luigi

AU - Torbenson, Michael

AU - Vierling, John M.

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Despite advances in understanding and treatment of autoimmune hepatitis, important unmet clinical needs remain in both adult and paediatric patient populations. The evolving research landscape and assembly of large patient cohorts are creating unique opportunities to translate science into new therapies and care pathways, with the potential to substantially improve the lives of patients with autoimmune hepatitis. However, these areas of unmet need represent real challenges that need to be addressed if this vision is to be realised. In this Viewpoint, we outline the challenges in adult autoimmune hepatitis, particularly in relation to disease-modifying therapy, and trial design and delivery. Paediatric autoimmune hepatitis presents its own set of challenging problems.

AB - Despite advances in understanding and treatment of autoimmune hepatitis, important unmet clinical needs remain in both adult and paediatric patient populations. The evolving research landscape and assembly of large patient cohorts are creating unique opportunities to translate science into new therapies and care pathways, with the potential to substantially improve the lives of patients with autoimmune hepatitis. However, these areas of unmet need represent real challenges that need to be addressed if this vision is to be realised. In this Viewpoint, we outline the challenges in adult autoimmune hepatitis, particularly in relation to disease-modifying therapy, and trial design and delivery. Paediatric autoimmune hepatitis presents its own set of challenging problems.

UR - http://www.scopus.com/inward/record.url?scp=85044920026&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044920026&partnerID=8YFLogxK

U2 - 10.1016/S2468-1253(18)30043-8

DO - 10.1016/S2468-1253(18)30043-8

M3 - Comment/debate

VL - 3

SP - 363

EP - 370

JO - The Lancet Gastroenterology and Hepatology

JF - The Lancet Gastroenterology and Hepatology

SN - 2468-1253

IS - 5

ER -